Document is current
Any future updates will be listed below
-
Authors
Chang, Ching-Pang
Chang, Ya-Gin
Chuang, Pei-Yun
Nguyen, Thi Ngoc Anh
Wu, Kuo-Chen
Chou, Fang-Yi
Cheng, Sin-Jhong
Chen, Hui-Mei
Jin, Lee-Way
Carvalho, Kevin
Huin, Vincent
Buée, Luc
Liao, Yung-Feng
Lin, Chun-Jung
Blum, David
Chern, Yijuang https://orcid.org/0000-0002-5842-5429
-
Funding
Funding for this research was provided by:
Academia Sinica (AS-SUMMIT-109, AS-KPQ-109-BioMed, AS-CFII-108-106)
Ministry of Science and Technology, Taiwan (MOST 107-2320-B-001-013-MY3, MOST-108-3114-Y-001-002)
National Institutes of Health (P30-AG010129)
Agence Nationale de la Recherche (ADORASTrAU ANR-18-CE16-0008, CoEN 5008)
- License Information
-
More Information
Article History
Received: 21 April 2021
Accepted: 7 June 2021
First Online: 22 June 2021
Ethical approval and consent to participate
: All animal studies were conducted following the protocols approved by the Institutional Animal Care and Utilization Committee (IACUC, Academia Sinica, Taiwan). Human brain samples were obtained from the UC Davis Alzheimer’s Disease Center (USA) and the brain banks of Lille, Paris, and Geneva. The IRB number of Academic Sinica is AS-IRB-BM-16013.
: Not applicable.
: Yijuang Chern hold patents on J4 for the treatment of neurodegenerative diseases.
